A novel benzene sulfonamide compound named IMB16-4 exhibits excellent anti-hepatic fibrosis activity in a recent study. To develop potential anti-hepatic fibrosis agents, a series of benzene sulfonamide derivatives were designed and synthesized based on the scaffold of the lead compound IMB16-4. As it turned out, most of the derivatives displayed potential anti-hepatic fibrosis activity, among which, compounds 11a, 11b, 11d, 13a, 36b, and 47b exhibited inhibition rates of 42.3%, 48.7%, 42.4%, 40.0%, 39.4%, and 49.3%, respectively, which were equivalent to the control IMB16-4 with an inhibition rate of 35.9%, Costunolide with an inhibition rate of 45.4%, and much more potent than that of Epigallocatechin gallate (EGCG) with an inhibition rate of 25.3%. Especially, compounds 46a, 46b, and 46c exhibited excellent anti-hepatic fibrosis activity with inhibition rates of 61.7%, 54.8%, and 60.7%, which were almost 1.5-fold inhibition rates of IMB16-4. In addition, compounds 46a, 46b, and 46c exhibited remarkable inhibitory activity in the gene expression of COL1A1, MMP-2, and the protein expression of COL1A1, FN, α-SMA, and TIMP-1 by inhibiting the JAK1-STAT1/3 pathway. These findings furnished valuable inspiration for the further development of anti-hepatic fibrosis agents.

在最近的一项研究中，一种名为IMB16-4的新型苯磺酰胺化合物表现出优异的抗肝纤维化活性。为了开发潜在的抗肝纤维化药物，基于先导化合物IMB16-4的支架设计并合成了一系列苯磺酰胺衍生物。事实证明，大多数衍生物显示出潜在的抗肝纤维化活性，其中化合物11a、11b、11d、13a、36b和47b的抑制率分别为42.3%、48.7%、42.4%、40.0%、39.4 % 和 49.3%，分别相当于对照IMB16-4抑制率为 35.9%，Costunolide 抑制率为 45.4%，比表没食子儿茶素没食子酸酯 (EGCG) 的抑制率为 25.3% 更有效。特别地，化合物46a、 46b和46c表现出优异的抗肝纤维化活性，抑制率分别为61.7%、54.8%和60.7%，几乎是IMB16-4抑制率的1.5倍。此外，化合物46a、 46b和46c对COL1A1、MMP-2的基因表达和COL1A1的蛋白表达均表现出显着的抑制活性，FN、α-SMA 和 TIMP-1 通过抑制 JAK1-STAT1/3 通路。这些发现为进一步开发抗肝纤维化药物提供了宝贵的启发。